Saltikva for Metastatic Pancreatic Cancer

Summary

Objectives: Assess the efficacy of multiple dose oral administration of Saltikva, an attenuated strain of Salmonella Typhimurium expressing IL-2, in patients with metastatic pancreatic cancer on standard chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane and Saltikva). Study Rationale: The addition of Saltikva to the standard of care regimen for Stage IV metastatic pancreatic cancer will significantly prolong the overall survival and prolong the time to disease progression. Patient Population: unresectable, metastatic pancreatic cancer patients 18 years of age or older

Timeline

Start

2020-10-20

Primary completion

2030-12-31

Completion

2030-12-31

Publications

• Batist G, Kavan P, Augustin L, Schottel J, Moradian J, Lee JT, Saltzman D. A phase 2 study of orally administered live biotherapeutic salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancer. Cancer Immunol Immunother. 2026 Jan 27;75(2):60. doi: 10.1007/s00262-026-04307-0.

Drugs

Indications